Chronic DiseaseCHIROPMEVNCT03827031
Impact of Mulstidisciplinary Medication Assessment Review in Surgery Departments
A study testing Mutlidisciplinary medication Review (MMR) and Mutlidisciplinary medication Review (MMR) with community pharmacist follow-up in people with Chronic Disease, run by Centre Hospitalier Universitaire de Nīmes at 4 sites in France.
Trial summary
The presence of a clinical pharmacist (for their pharmacological expertise) and a general practitioner (for their somatic expertise) in surgery departments would contribute to improve the management of medications in elderly patients. Read more about this study
- Who is it for?
- Ages 65 years and older
- Conditions the study is for
- Chronic Disease
- What is being tested?
- Mutlidisciplinary medication Review (MMR) and Mutlidisciplinary medication Review (MMR) with community pharmacist follow-up
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 297 participants
- Where
- 4 sitesFrance
- Study dates
- 18 Jul 2022to Jul 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 65 years and older
- All sexes
- No healthy volunteers
- Older adult
Who may be able to join
- The patient (or their representative) has given his consent and signed the consent form.
- The patient is affiliated to a health insurance programme.
- The patient is at least 65 years old (≥) treated by at least (≥) five medications for at least (≥) 6 months
- The patient is available for a follow-up of 3 months.
- The patient is hospitalized in the surgery department.
- Patient with a Trivalle score greater than or equal to 2 (≥).
- Patient living in a nursing home or going back home after hospitalization.
Who cannot join
- The subject is participating in another category I interventional study.
- The subject is in an exclusion period determined by another study.
- The subject is under safeguard of justice.
- It is not possible to give the patient (or his/her trusted-person) informed information.
- Palliative care
Trial locations and contacts
4 sites in 1 country. Contact the study team or a site near you to ask about taking part.
France4 sites, 4 recruiting
- Not yet recruiting
Chu de Grenoble
Grenoble, 38043
Pierrick BEDOUCH, 04 76 76 54 97, PBedouch@chu-grenoble.fr
- Recruiting
CHU de Montpellier
Montpellier
Maxime Villiet, 04 67 33 85 62, m-villiet@chu-montpellier.fr
Maxime Villiet
- Recruiting
Nimes University Hospital
Nîmes, 30029
Anissa Megzari, +33 (0)4.66.68.42.36, drc@chu-nimes.fr
Géraldine LEGUELINEL-BLACHE, PharmaD
- Recruiting
CHU de Toulouse
Toulouse
Julien Jouglen, 05 67 77 10 55, jouglen.j@chu-toulouse.fr
Julien Jouglen
About this study
Official title: Implementation and Impact of Multidisciplinary Medication Review in Surgery Departments on Medication Management of Elderly Patients
The presence of a clinical pharmacist (for their pharmacological expertise) and a general practitioner (for their somatic expertise) in surgery departments would contribute to improve the management of medications in elderly patients.
- Conditions
- Chronic Disease
- Being tested
- Mutlidisciplinary medication Review (MMR), Mutlidisciplinary medication Review (MMR) with community pharmacist follow-up
- Keywords
- Drug Safety, Clinical Pharmacy, General Practice, Surgery, Geriatrics, Medication Review
- Medical subject headings
- Chronic Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Mutlidisciplinary medication Review (MMR)Other
The clinical pharmacist performs medication reconciliation and pharmaceutical analysis. The physician performs a clinical examination and analysis of the medical record. Both participate in a collaborative interview. The hospital physician calls the community pharamcist to discuss proposed changes on the order and to establish a new prescription. At the end of the stay, the clinical pharmacist will conduct an exit interview with the patient. Three months after discharge, the patient's community pharmacist will be contacted to assess whether the changes proposed in the MMR were accepted
Mutlidisciplinary medication Review (MMR) with community pharmacist follow-upOther
Multidisciplinary medication review (MMR) The clinical pharmacist performs medication reconciliation and pharmaceutical analysis. The physician performs a clinical examination and analysis of the medical record. Both participate in a collaborative interview. The hospital physician calls the community physician to discuss proposed changes on the order and to establish a new prescription. At the end of the stay, the clinical pharmacist will conduct an exit interview with the patient.
Community follow-up A summary of the follow-up report stating the therapeutic modifications (called below multidisciplinary correspondence documents) will be sent to the community pharmacist and physician. Within 2 months of discharge, the pharmacist performs a follow-up of medication changes accepted and not accepted by the community physician.
Three months after discharge, the patient's community pharmacist will be contacted to assess whether the changes proposed in the MMR were accepted.
| Study group | Role | What they receive |
|---|---|---|
| Control group | No intervention | Not described |
| B1 interventional group | Experimental | Not described Receives: Other: Mutlidisciplinary medication Review (MMR) |
| B2 interventional group | Experimental | Not described Receives: Other: Mutlidisciplinary medication Review (MMR); Other: Mutlidisciplinary medication Review (MMR) with community pharmacist follow-up |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in iatrogenic drug risk in intervention groups versus control group
Proportion of patients transitioning from intermediate or high to low risk according to Trivalle score (a score between 0-10. A score 0-1 constitutes a low ADE risk (12%), score 2-5 represents an average risk (32%), and a score 6-10 represents a high risk (53%)
Measured: 3 months after hospitalization
Secondary outcomes (15)
Proportion of proposed medication modifications made by the clinical pharmacist accepted by the clinical doctor during the Multidisciplinary Medication Review in the experimental groups
Number of modifications accepted/number of modifications proposed
Measured: Hospital discharge (maximum 30 days)
Number of potentially inappropriate medications per patient in each group
Measured: Hospital discharge (maximum 30 days)
Proportion of proposed medication modifications made by the collaborative team accepted and/or made permanent
Number of modifications accepted/number of modifications proposed
Measured: 3 months after hospital discharge
Number of potentially inappropriate medications per patient in each group
Measured: 3 months after hospital discharge
Time required for Multidisciplinary Medication Review in the interventional groups (B1 and B2)
Hours
Measured: Hospital discharge (maximum 30 days)
Time required for ransmitting multidisciplinary correspondence documents in B2 group
Hours
Measured: Hospital discharge (maximum 30 days)
Number of multidisciplinary correspondence documents sent to the community acotors in B2 group
Measured: Hospital discharge (maximum 30 days)
Description of mode of diffusion of multidisciplinary correspondence documents in the B2 group
email, fax or letter
Measured: Hospital discharge (maximum 30 days)
Description of reason for non-transmission of multidisciplinary correspondence documents in the B2 group
Measured: Hospital discharge (maximum 30 days)
Rate of patients for whom a follow-up review of proposed medication changes has been performed by the pharmacist in the B2 group
Measured: 2 months post discharge
Number of multidisciplinary correspondence documents transmitted by community pharmacist in group B2
Measured: 2 months post hospital discharge
Rate of patients with at least one rehospitalization in each group
Measured: 3 months after hospital discharge
Mortality rate in each group
Measured: 3 months after hospital discharge
Healthcare team satisfaction in interventional groups (B1, B2)
Custom-built 7-part questionnaire
Measured: 3 months after hospital discharge
patient satisfaction in all groups (A, B1, B2)
questionnaire
Measured: 3 months after hospital discharge
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Feb 2019
- Study start18 Jul 2022
- Primary completionJul 2027 (estimated)
- Study completionJul 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Chronic DiseaseStudies of the same condition, open and under way.
- More trials run by Centre Hospitalier Universitaire de NīmesThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 297 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Centre Hospitalier Universitaire de Nīmes
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Jean-Marie Kinowski, Principal investigator, Nîmes University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03827031
- Sponsor's protocol ID
- NIMAO/2017-02/JMK-01
- Acronym
- CHIROPMEV
- Status last verified
- Aug 2025
- First submitted
- 22 Aug 2018
- Last updated
- 20 Aug 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 20 Aug 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Implementation and Impact of Multidisciplinary Medication Review in Surgery Departments on Medication Management of Elderly Patients
- ClinicalTrials.gov ID
- NCT03827031
- Acronym / sponsor ID
- CHIROPMEV / NIMAO/2017-02/JMK-01
- Conditions
- Chronic Disease
- Keywords
- Drug Safety, Clinical Pharmacy, General Practice, Surgery, Geriatrics, Medication Review
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 297 participants (estimated)
- Lead sponsor
- Centre Hospitalier Universitaire de NīmesUniversity, hospital or other
- Study start
- 18 Jul 2022 (actual)
- Primary completion
- Jul 2027 (estimated)
- Study completion
- Jul 2027 (estimated)
- First posted
- 1 Feb 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The presence of a clinical pharmacist (for their pharmacological expertise) and a general practitioner (for their somatic expertise) in surgery departments would contribute to improve the management of medications in elderly patients.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Control group | No intervention | – |
| B1 interventional group | Experimental | Other: Mutlidisciplinary medication Review (MMR) |
| B2 interventional group | Experimental | Other: Mutlidisciplinary medication Review (MMR), Other: Mutlidisciplinary medication Review (MMR) with community pharmacist follow-up |
Who may qualify
- Ages
- 65 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Older adult
Key inclusion criteria (7 listed)
- The patient (or their representative) has given his consent and signed the consent form.
- The patient is affiliated to a health insurance programme.
- The patient is at least 65 years old (≥) treated by at least (≥) five medications for at least (≥) 6 months
- The patient is available for a follow-up of 3 months.
- The patient is hospitalized in the surgery department.
Key exclusion criteria (5 listed)
- The subject is participating in another category I interventional study.
- The subject is in an exclusion period determined by another study.
- The subject is under safeguard of justice.
- It is not possible to give the patient (or his/her trusted-person) informed information.
- Palliative care
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Mutlidisciplinary medication Review (MMR)The clinical pharmacist performs medication reconciliation and pharmaceutical analysis. The physician performs a clinical examination and analysis of the medical record. Both participate in a collaborative interview. The hospital physician calls the community pharamcist to discuss proposed changes on the order and to establish a new prescription. At the end of the stay, the clinical pharmacist will conduct an exit interview with the patient. Three months after discharge, the patient's community pharmacist will be contacted to assess whether the changes proposed in the MMR were accepted | Other | B1 interventional group, B2 interventional group |
| Mutlidisciplinary medication Review (MMR) with community pharmacist follow-upMultidisciplinary medication review (MMR) The clinical pharmacist performs medication reconciliation and pharmaceutical analysis. The physician performs a clinical examination and analysis of the medical record. Both participate in a collaborative interview. The hospital physician calls the community physician to discuss proposed changes on the order and to establish a new prescription. At the end of the stay, the clinical pharmacist will conduct an exit interview with the patient. Community follow-up A summary of the follow-up report stating the therapeutic modifications (called below multidisciplinary correspondence documents) will be sent to the community pharmacist and physician. Within 2 months of discharge, the pharmacist performs a follow-up of medication changes accepted and not accepted by the community physician. Three months after discharge, the patient's community pharmacist will be contacted to assess whether the changes proposed in the MMR were accepted. | Other | B2 interventional group |
Primary outcome
Change in iatrogenic drug risk in intervention groups versus control group
Time frame: 3 months after hospitalization
Proportion of patients transitioning from intermediate or high to low risk according to Trivalle score (a score between 0-10. A score 0-1 constitutes a low ADE risk (12%), score 2-5 represents an average risk (32%), and a score 6-10 represents a high risk (53%)
15 secondary outcomes
Proportion of proposed medication modifications made by the clinical pharmacist accepted by the clinical doctor during the Multidisciplinary Medication Review in the experimental groups
Time frame: Hospital discharge (maximum 30 days)
Number of potentially inappropriate medications per patient in each group
Time frame: Hospital discharge (maximum 30 days)
Proportion of proposed medication modifications made by the collaborative team accepted and/or made permanent
Time frame: 3 months after hospital discharge
Number of potentially inappropriate medications per patient in each group
Time frame: 3 months after hospital discharge
Time required for Multidisciplinary Medication Review in the interventional groups (B1 and B2)
Time frame: Hospital discharge (maximum 30 days)
Time required for ransmitting multidisciplinary correspondence documents in B2 group
Time frame: Hospital discharge (maximum 30 days)
Number of multidisciplinary correspondence documents sent to the community acotors in B2 group
Time frame: Hospital discharge (maximum 30 days)
Description of mode of diffusion of multidisciplinary correspondence documents in the B2 group
Time frame: Hospital discharge (maximum 30 days)
Description of reason for non-transmission of multidisciplinary correspondence documents in the B2 group
Time frame: Hospital discharge (maximum 30 days)
Rate of patients for whom a follow-up review of proposed medication changes has been performed by the pharmacist in the B2 group
Time frame: 2 months post discharge
Number of multidisciplinary correspondence documents transmitted by community pharmacist in group B2
Time frame: 2 months post hospital discharge
Rate of patients with at least one rehospitalization in each group
Time frame: 3 months after hospital discharge
Mortality rate in each group
Time frame: 3 months after hospital discharge
Healthcare team satisfaction in interventional groups (B1, B2)
Time frame: 3 months after hospital discharge
patient satisfaction in all groups (A, B1, B2)
Time frame: 3 months after hospital discharge
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Aug 2025.
Related trials for Chronic Disease
RecruitingPhase 2
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Not yet recruiting
Feasibility of a Robot-Guided Active Play Intervention for Children With Cerebral Palsy
Cerebral Palsy
Recruiting
PAW-Hydrogel for Chronic Wound Healing
Diabetic Foot Ulcer (DFU), Pressure Ulcer (PU)
Active, not recruitingPhase 2
Safety and Efficacy of Empagliflozin in Hemodialysis
End Stage Renal Disease
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Jean-Marie Kinowski principal investigator
Nîmes University Hospital
4 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Mutlidisciplinary medication Review (MMR) and Mutlidisciplinary medication Review (MMR) with community pharmacist follow-up in people with Chronic Disease, run by Centre Hospitalier Universitaire de Nīmes at 4 sites in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 20 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 4 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Jean-Marie Kinowski (+33(0)4.66.68.31.04, jean.marie.kinowski@chu-nimes.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in iatrogenic drug risk in intervention groups versus control group (time frame: 3 months after hospitalization). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Aug 2025.